Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study

Kerem Ozturk, Esra Soylu, Sahsine Tolunay, Selin Narter, Bahattin Hakyemez

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objective: We aimed to evaluate the usefulness of dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging (DCE-pMRI) to predict certain immunohistochemical (IHC) biomarkers of glioblastoma (GB) in this pilot study. Methods: We retrospectively reviewed 36 patients (male/female, 25:11; mean age, 53 years; age range, 29–85 years) who had pretreatment DCE-pMRI with IHC analysis of their excised GBs. Regions of interest of the enhancing tumor (ER) and nonenhancing peritumoral region (NER) were used to calculate DCE-pMRI parameters of volume transfer constant, back flux constant, volume of the extravascular extracellular space, initial area under enhancement curve, and maximum slope. IHC biomarkers including Ki-67 labeling index, epidermal growth factor receptor (EGFR), oligodendrocyte transcription factor 2 (OLIG2), isocitrate dehydrogenase 1 (IDH1), and p53 mutation status were determined. The imaging metrics of GB with IHC markers were compared using the Kruskal-Wallis test and Spearman correlation analysis. Results: Among 30 patients with available IDH1 status, 14 patients (46.6%) had IDH1 mutation. EGFR amplification was present in 24/36 (66.6%) patients. Mean Ki-67 labeling index was 29% (range, 1.5%–80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). Various DCE-pMRI parameters gathered from the ER and NER were significantly correlated with IDH1 mutation, EGFR amplification, and OLIG2 expression (P <0.05). Ki-67 labeling index showed a strong positive correlation with initial area under enhancement curve (r = 0.619; P <0.001). Conclusions: DCE-pMRI could determine surrogate IHC biomarkers in GB via tumoral and peritumoral approach, potential targets for individualized treatment protocols.
Original languageEnglish (US)
JournalWorld neurosurgery
Volume128
DOIs
StatePublished - Aug 2019

Bibliographical note

Publisher Copyright:
© 2019

Keywords

  • Dynamic contrast-enhanced T1-weighted perfusion MR imaging (DCE-pMRI)
  • Epidermal growth factor receptor (EGFR)
  • Glioblastoma (GB)
  • Isocitrate dehydrogenase 1 (IDH1)
  • Oligodendrocyte transcription factor 2 (OLIG2)

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study'. Together they form a unique fingerprint.

Cite this